{"filing":{"accession_number":"0001213900-26-095310","cik":"0001075880","ticker":"KZIA","company_name":"KAZIA THERAPEUTICS LTD","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"ea0303820-6k_kazia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026095310/ea0303820-6k_kazia.htm"},"events":[{"id":30462,"run_id":27916,"accession_number":"0001213900-26-095310","anchor_item_number":"EX-99.2","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Kazia announced a registered public offering of 2,580,000 ADSs (representing 1.29 billion ordinary shares) plus Series A and Series B Warrants, with expected gross proceeds of approximately $40 million before underwriting costs and potential additional proceeds of ~$80 million if warrants are exercised. The offering is tranched and involves dilutive equity issuance to raise capital for clinical development.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33060,"accession_number":"0001213900-26-095310","item_number":"EX-99.1","item_title":"ea030382001ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Kazia announced a registered public offering of American Depositary Shares (ADSs), pre-funded warrants, and Series A and B Warrants under Form F-3. The offering is tranched and involves dilutive equity issuance to raise capital for clinical development. This is a material capital-raising event that would affect investor assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:02:16.620703+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33061,"accession_number":"0001213900-26-095310","item_number":"EX-99.2","item_title":"ea030382001ex99-2.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a pricing press release announcing a registered public offering of 2,580,000 ADSs (representing 1.29 billion ordinary shares) plus accompanying Series A and Series B Warrants, with expected gross proceeds of approximately $40 million before underwriting costs and potential additional proceeds of ~$80 million if warrants are exercised. The offering is dilutive to existing shareholders and material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:02:16.620703+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33060,"accession_number":"0001213900-26-095310","item_number":"EX-99.1","item_title":"ea030382001ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Kazia announced a registered public offering of American Depositary Shares (ADSs), pre-funded warrants, and Series A and B Warrants under Form F-3. The offering is tranched and involves dilutive equity issuance to raise capital for clinical development. This is a material capital-raising event that would affect investor assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:02:16.620703+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-31"},{"id":33061,"accession_number":"0001213900-26-095310","item_number":"EX-99.2","item_title":"ea030382001ex99-2.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a pricing press release announcing a registered public offering of 2,580,000 ADSs (representing 1.29 billion ordinary shares) plus accompanying Series A and Series B Warrants, with expected gross proceeds of approximately $40 million before underwriting costs and potential additional proceeds of ~$80 million if warrants are exercised. The offering is dilutive to existing shareholders and material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:02:16.620703+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-31"}]}